Aktienanalyse zu Eledon Pharmaceuticals Inc (ELDN)ELDNEledon Pharmaceuticals Inc

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Eledon Pharmaceuticals Inc is a good buy right now due to its current price of $2.62, which is significantly below the analyst price target of $12, indicating a potential upside of 200%. Additionally, the stock has shown a strong year-to-date change of +61.73%, suggesting positive momentum. The RSI is at 54.03, indicating that the stock is neither overbought nor oversold, which is favorable for entry. However, the main risk is the negative earnings per share (EPS) forecast of -0.20 for the next earnings report on November 13, 2026, which could impact investor sentiment.